NasdaqGS - Delayed Quote USD

Royalty Pharma plc (RPRX)

Compare
28.21 -0.03 (-0.11%)
At close: 4:00 PM EDT
28.21 0.00 (0.00%)
After hours: 4:02 PM EDT
Loading Chart for RPRX
DELL
  • Previous Close 28.24
  • Open 28.17
  • Bid 28.19 x 300
  • Ask 28.24 x 400
  • Day's Range 28.14 - 28.46
  • 52 Week Range 25.20 - 31.66
  • Volume 1,181,489
  • Avg. Volume 2,657,833
  • Market Cap (intraday) 16.741B
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) 18.81
  • EPS (TTM) 1.50
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield 0.84 (2.97%)
  • Ex-Dividend Date Aug 16, 2024
  • 1y Target Est 44.83

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

www.royaltypharma.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RPRX

View More

Performance Overview: RPRX

Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RPRX
2.70%
S&P 500
17.79%

1-Year Return

RPRX
3.32%
S&P 500
26.24%

3-Year Return

RPRX
21.41%
S&P 500
26.74%

5-Year Return

RPRX
35.89%
S&P 500
79.80%

Compare To: RPRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RPRX

View More

Valuation Measures

Annual
As of 9/17/2024
  • Market Cap

    12.66B

  • Enterprise Value

    17.70B

  • Trailing P/E

    18.83

  • Forward P/E

    9.29

  • PEG Ratio (5yr expected)

    15.22

  • Price/Sales (ttm)

    7.55

  • Price/Book (mrq)

    1.95

  • Enterprise Value/Revenue

    7.91

  • Enterprise Value/EBITDA

    14.56

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    30.09%

  • Return on Assets (ttm)

    3.45%

  • Return on Equity (ttm)

    10.53%

  • Revenue (ttm)

    2.24B

  • Net Income Avi to Common (ttm)

    673.24M

  • Diluted EPS (ttm)

    1.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.8B

  • Total Debt/Equity (mrq)

    77.96%

  • Levered Free Cash Flow (ttm)

    -1.66B

Research Analysis: RPRX

View More

Company Insights: RPRX

Research Reports: RPRX

View More

People Also Watch